Ikegami T, Nicholson G, Ikeda H, Ishida A, Johnston H, Wise G, Ouvrier R, Hayasaka K
Department of Pediatrics, Yamagata University School of Medicine, Japan.
Biochem Biophys Res Commun. 1996 May 6;222(1):107-10. doi: 10.1006/bbrc.1996.0705.
We have previously reported that heterozygosity for myelin Po gene mutations were associated with Charcot-Marie-Tooth disease type 1B (CMT1B) or Dejerine-Sottas disease. We investigated the Po gene in a family with clinical Dejerine-Sottas disease and found two children were homozygous for a deletion of Phe 64. The parents were heterozygous first cousins with subclinical CMT1B and slow nerve conduction velocities. These results suggest that the effect of homozygous Phe 64 deletion on impairment of myelination is dosage-dependent. Clinical phenotype and/or myelin impairment may be determined both by the type of mutation and by the dosage of mutated gene.
我们之前曾报道,髓磷脂蛋白零(Po)基因突变的杂合性与1B型腓骨肌萎缩症(CMT1B)或德热里纳 - 索塔斯病相关。我们对一个患有临床德热里纳 - 索塔斯病的家族进行了Po基因研究,发现两个孩子为苯丙氨酸64缺失的纯合子。父母是患有亚临床CMT1B且神经传导速度缓慢的杂合子近亲。这些结果表明,苯丙氨酸64纯合缺失对髓鞘形成损伤的影响是剂量依赖性的。临床表型和/或髓鞘损伤可能由突变类型和突变基因的剂量共同决定。